Iliofemoral venous stenoses: Effectiveness of treatment with metallic endovascular stents

Gwen K. Nazarian, Haraldur Bjarnason, Charles A Dietz, Casandra Anderson Bernadas, David W. Hunter

Research output: Contribution to journalArticlepeer-review

123 Scopus citations


PURPOSE: To assess effectiveness of metallic endovascular stents in treatment of venous stenoses and occlusions. MATERIALS AND METHODS: Stents were placed intravenously in 56 patients (59 stenoses or occlusions) over a 6-year period. Stent sites included the inferior vena cava (n = 10) and common iliac (n = 31), external iliac (n = 46), common femoral (n = 27), and superficial femoral veins (n = 4). Indications for stent placement included stenoses from pelvic malignancy and its treatment; trauma, surgery, or pregnancy; and idiopathic stenoses. Patients underwent anticoagulation therapy for 3-6 months after stent placement. Follow-up was performed with duplex ultrasound. RESULTS: With use of life-table analysis, overall primary and secondary 1-year patency rates were 50% and 81%, respectively. Primary and secondary 4-year patency rates were and 50% and 75%, respectively. Five patients died of primary disease progression within 6 months after stent placement. Major complications occurred in 6.8% of cases. One-year secondary patency rates were statistically significantly lower (P =.05) for patients with malignant disease, although primary patency rates were comparable. Overall sustained decrease in symptoms (P <.0001) was observed 1 year later. CONCLUSION: Endovascular stent placement is a nonsurgical alternative for reestablishment of venous flow and sustained relief of symptoms in patients with malignant or benign pelvic venous disease.

Original languageEnglish (US)
Pages (from-to)193-199
Number of pages7
Issue number1
StatePublished - Jul 1996


  • Stents and prostheses
  • Thrombosis, venous
  • Veins, abnormalities
  • Veins, transluminal angioplasty


Dive into the research topics of 'Iliofemoral venous stenoses: Effectiveness of treatment with metallic endovascular stents'. Together they form a unique fingerprint.

Cite this